Research use only. This page is education, not medical advice. It reports what registered trials have published; it does not evaluate the safety of any product sold outside those trials.

Short answer: Eloralintide’s Phase 2 trial reported mild to moderate nausea (11% to 64% by dose arm) and fatigue (0% to 46%) as the most common adverse events, with about 10% of participants stopping treatment because of one. A smaller Phase 1b study also reported four participants with mood-related events at higher doses. No safety data beyond 48 weeks has been published, and no Phase 3 safety results exist yet.

• Any adverse event occurred in 81% of active-arm participants versus 71% on placebo over 48 weeks.
• Four participants in a 12-week Phase 1b study had mood-related events (three depressed mood, one persistent depressive disorder), all at 6mg or 12mg doses; the three at 12mg stopped treatment, and events resolved in two to four days.
• In obese rats, eloralintide preserved more lean mass than cagrilintide at comparable doses — a preclinical signal that has not been confirmed with human body-composition data.
• Long-term safety (beyond 48 weeks) is unknown; ENLIGHTEN-1 and the other Phase 3 trials are designed to run through 2030.

Last verified October 2026. Sources are listed at the end. For laboratory and research use only. Nothing here is medical or legal advice.

Most commonly reported adverse events

In Lilly’s Phase 2 trial (NCT06230523), the most frequently reported adverse events across active-dose arms were mild to moderate nausea and fatigue. Nausea reportedly ranged from 11% to 64% by dose arm (versus 14% on placebo), and fatigue from 0% to 46% (versus 12% on placebo). Any adverse event occurred in 81% of participants on active doses versus 71% on placebo, and about 10% of participants discontinued treatment because of an adverse event. This pattern is broadly consistent with other amylin- and incretin-class compounds, where gastrointestinal side effects are the most common tolerability issue, particularly during dose initiation and titration.

A separate, smaller 12-week Phase 1b study also reported decreased appetite (19.2% of participants), headache (12.3%), diarrhoea (9.6%), and injection site reactions (9.6%).

Mood-related events reported in Phase 1b

The same 12-week Phase 1b study reported four participants with mood-related events: three with depressed mood and one with persistent depressive disorder, all occurring at the 6mg or 12mg dose levels. The three participants at the 12mg dose discontinued treatment, and the reported events resolved within two to four days. The published data do not establish a causal link between eloralintide and these events, and the sample size is small; it would be equally inaccurate to claim eloralintide has “no mood effects” or to claim a confirmed causal link based on this record. Larger, longer trials will be needed to clarify this signal.

Tolerability compared to other amylin-class compounds

Preclinical data in obese rats found that eloralintide produced 86% to 91% fat-mass loss (as a share of total weight lost) at low and middle doses, compared with 63% for cagrilintide at its test dose, with significantly lower lean-mass loss on eloralintide. A 2026 review of amylin-based therapies lists preferential fat-mass loss among eloralintide’s early distinguishing features, drawing on this same animal data. These are preclinical, animal-model findings, not confirmed human clinical results, and should be treated as early signals rather than established facts about eloralintide’s human safety or body-composition profile.

What hasn’t been established yet

Eloralintide’s Phase 2 program was a 48-week study in a specific, relatively narrow population (adults with obesity or overweight, without type 2 diabetes). Longer-term safety data, safety in broader or more diverse populations, bone and immune-response effects, weight regain after stopping treatment, and detailed rates of less-common adverse events typically become available later in Phase 3 and in subsequent regulatory review, if the compound reaches that stage. As of this writing, no Phase 3 safety data has been published; the lead ENLIGHTEN-branded Phase 3 trials are registered to run through 2030.

Why there’s no personal safety guidance on this page

Eloralintide is not approved for human use and is not available outside of registered clinical trials, where participants are monitored by trial investigators under informed consent. This page summarizes what has been publicly reported about trial-level adverse events; it is not medical advice, and it does not evaluate the safety of any product marketed online as “eloralintide” for personal use, since no such product is part of an approved or regulated supply chain.

Sources

All sources read and verified October 2026.

• Billings LK, et al. Eloralintide Phase 2. The Lancet 2025. DOI: 10.1016/S0140-6736(25)02155-5. ClinicalTrials.gov NCT06230523.
• Bhattachar S, et al. Diabetes, Obesity and Metabolism 2026 (Phase 1b data). PMC12992164.
• Briere DA, et al. Molecular Metabolism 2025 (preclinical body-composition data). PMC12640043.
• Novel amylin-based therapies network meta-analysis. Endocrinology, Diabetes and Metabolism 2026. PMC13240113.